Fueled by Covid prospects, Chinese vaccine developer scores $230M to upscale the whole pipeline
Filed in Shanghai Travel News on February 24, 2021 with no comments
The Covid tides are floating more than US or European boats.
Take Clover Biopharmaceuticals, the Chengdu, China-based developer of a CEPI-funded vaccine that’s just closed $230 million in a Series C. That means the biotech is officially $400 million richer than it was before the pandemic struck — and potentially standing much closer to the commercial market.…
This data comes from the ChinaPulse.com media intelligence and smart news insights platform.